Comparative Pharmacology
Head-to-head clinical analysis: GLYCORT versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYCORT versus HICON.
GLYCORT vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to produce anti-inflammatory and immunosuppressive effects.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
Intravenous: 2 mg/kg every 12 hours; Oral: 20 mg twice daily.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
3.5 hours (terminal); prolonged in hepatic impairment (up to 8 hours) and severe renal impairment (up to 6 hours)
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Renal: 70% as unchanged drug; biliary/fecal: 25% (metabolites); 5% other
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category C
Category C
Anticholinergic
Anticholinergic